How best to combine new immunotherapies is a burning question in oncology. A new study in the CheckMate series suggests that nivolumab (Opdivo) and ipilimumab (Yervoy) can be safely and effectively combined as first-line treatment of advanced non–small cell lung cancer (NSCLC),1 but further study...
[The relatively small improvement in progression-free survival] leads me to question whether median progression-free survival is the best endpoint for trials of combination immunotherapy.— David R. Spigel, MD
“These are outstanding results,” commented formal discussant...!-->!-->
Effective and tolerable treatments are needed for older patients [with CLL], most of whom will die of the disease or its complications.— Vicki A. Morrison, MD
Significant progress has been made in the past 2 decades in the care of patients with chronic lymphocytic...!-->!-->
Our approach to radiation accident victims today is based largely on observations and contributions from these atomic hematologists and oncologists.… More importantly, readers surely know of the considerable supportive roles of erythropoietin, G-CSF, and hematopoietic cell...!-->!-->!-->!-->
The risk of recurrence in estrogen receptor–positive breast cancer is known to continue after 5 years, but just how much is that risk once endocrine therapy is stopped? The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) has concluded it is “appreciable,” with distant recurrences...
In the group that is arguably the best among these women—those presenting with T1N0 tumors—we see a steady increase in the [event] line, and it doesn’t seem to waver in any fashion.— Nancy E. Davidson, MD
Nancy E. Davidson, MD, the Hillman Professor of Oncology and...!-->!-->
Richard Pazdur, MD
Daniel F. Hayes, MD, ASCO President, issued the following statement on June 29, 2016:
“ASCO commends FDA Commissioner Dr. Robert Califf for his selection of Dr. Richard Pazdur to lead the agency’s new Oncology Center of Excellence. In his nearly 20 years with the FDA,...!-->!-->
In patients with HER2-positive early breast cancer, pathologic complete response rates after neoadjuvant therapy were higher with docetaxel plus carboplatin plus trastuzumab (Herceptin) plus pertuzumab (Perjeta), or TCH+P, than with ado-trastuzumab emtansine (Kadcyla) plus pertuzumab, or T-DM1+P,...
It’s reasonable to consider nab-paclitaxel over solvent-based paclitaxel, to eliminate steroids and allergic reactions, but … that is offset by increased cost.— Stephen K.L. Chia, MD
Stephen K.L. Chia, MD, of the British Columbia Cancer Agency, Vancouver, discussed two...!-->!-->
We know that metastatic breast cancer survival is much better now than 20 years ago, but we also know there’s a role for surgery of the primary tumor.— Atilla Soran, MD, MPH
For de novo stage IV breast cancer, does resection of the primary tumor improve outcomes? Two...!-->!-->
We really have no data to suggest any benefit from surgery. We also know that patients with estrogen receptor/progesterone receptor–positive or HER2-positive disease are more likely to benefit from targeted therapy….— Elizabeth Mittendorf, MD, PhD
The discussant of...!-->!-->
U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, MD, issued the following statement June 29, 2016, regarding the appointment of Richard Pazdur, MD, as the Acting Director of the FDA Oncology Center of Excellence. Dr. Pazdur is currently Director of the Office of Oncology...
Chimeric antigen receptor (CAR) T-cell therapy has been effective in adults and children with advanced acute lymphoblastic leukemia (ALL), but along with efficacy, the treatment can stimulate cytokine-release syndrome, which can be deadly if it goes unrecognized and untreated. Adjusting the dose...
Response rates are high but so are relapse rates. CAR T-cell therapy may ultimately be better applied in patients with persistent minimal residual disease.— Steven M. Devine, MD
Formal discussant of these trials Steven M. Devine, MD, of The Ohio State University...!-->!-->
We were completely taken by surprise when we received the data.… These findings should expand treatment choices and change the way we treat patients with this rare form of brain cancer.— Martin J. Van Den Bent, MD, PhD
Adjuvant temozolomide, after radiotherapy, improves ...!-->!-->
We see a significant separation of the curves favoring the administration of adjuvant temozolomide, and at the landmarks of 2 and 5 years, and the difference in outcomes appears to be growing.— David Reardon, MD
“Adjuvant temozolomide does represent a new standard of...!-->!-->
W.K. Alfred Yung, MD
National Brain Tumor Society (NBTS) has announced the appointment of W.K. Alfred Yung, MD, as Special Advisor to the Chief Executive Officer (CEO). Dr. Yung, the outgoing Chair of the Neuro-Oncology Department at The University of Texas MD Anderson Cancer Center, will...!-->!-->
Atezolizumab (Tecentriq), an anti–programmed cell death ligand 1 (PD-L1) inhibitor, achieved durable responses as first-line treatment in cisplatin-ineligible patients with metastatic urothelial carcinoma in a primary analysis of a phase II trial. These data represent an unmet need, because...
Charles Ryan, MD
“These are important data. It is safe to envision a future where atezolizumab [Tecentriq] can be used first-line. These were cisplatin-ineligible patients, and many patients fall into this category, especially the elderly. Platinum-ineligibility is a big problem due to...!-->!-->
Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) presented study findings on a means of evaluating an immunotherapy for non–small cell lung cancer (NSCLC).1 Due to NSCLC’s relative insensitivity to chemotherapy, the use of immunotherapies,...
With surgical removal at the front line of defense against prostate cancer, oncologists are considering prostate-specific molecular imaging at the point of initial biopsy and preoperative planning to root out the full extent of disease, researchers showed at the 2016 Annual Meeting of the Society...
Patients with cancer often experience significant fluctuations in weight and lean body mass. Neglecting to account for these changes can prevent clinicians from obtaining precise data from molecular imaging, but a new method of measuring lean body mass takes changes in individual body composition...
Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) presented a molecular imaging methodology that allows the increase of the radiotherapy dose to the tumor while protecting vulnerable vital organs.1
The delicate balance of administering the...
Adolescent and Young Adult Oncology explores the unique physical, psychosocial, social, emotional, sexual, and financial challenges adolescents and young adults with cancer face. The column is guest edited by Brandon Hayes-Lattin, MD, FACP, Associate Professor of Medicine and...
James M. Ford, MD
ASCO recently announced the appointment of James M. Ford, MD, as Editor-in-Chief of the Society’s new journal, JCO Precision Oncology. Dr. Ford will set the scope and vision for the online-only journal, which will publish scientific and educational content that provides a ...!-->!-->
The American Association for Cancer Research (AACR) congratulates the four recipients of the inaugural NextGen Grants for Transformative Cancer Research.
The recipients were honored at the AACR Annual Meeting 2016, held April 16–20 in New Orleans.
“The AACR is very proud to announce the first...
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). For information on how you can submit your own essay for consideration in JCO’s Art of Oncology, visit
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with cardiotoxicity resulting from cancer or cancer treatment. These studies are investigating the effect of trastuzumab in survivors of breast cancer; the effects of...
The Multiple Myeloma Research Foundation (MMRF), a leader in precision medicine, has announced that its founder Kathy Giusti has been appointed Faculty Co-Chair of the Kraft Precision Medicine Accelerator at Harvard Business School (HBS).
Ms. Giusti will lead the Harvard...!-->!-->
Philip A. Pancari, MD
Philip A. Pancari, MD, has joined the Department of Hematology/Oncology at Fox Chase Cancer Center, providing additional physician support for the Fox Chase Cancer Center–Temple University Hospital Bone Marrow Transplant (BMT) Program.
“Having worked at Fox Chase for ...!-->!-->
At the end of June, Allen S. Lichter, MD, FASCO, retired after serving as ASCO’s Chief Executive Officer (CEO) for 10 years. To honor his commitment and contributions to ASCO and recognize his lasting impact on the field of oncology, the Society has created a new Special Award, the Allen S. Lichter ...
On June 1, 2016, ASCO announced that the Contemporary Oncology Team of Athens, Greece, as part of the new international pilot project, is the first international practice to receive Quality Oncology Practice Initiative (QOPI®) certification through QOPI Certification Program, LLC (QCP).
ASCO is committed to providing all oncologists with opportunities for professional development that will maximize their career success. In response to the recognized career gender gap for women in oncology, ASCO included a number of initiatives in the 2016 Annual Meeting program. In its 2nd year,...
The new ASCO Answers Guide to non–small cell lung cancer replaces the previous guide to general lung cancer. It is designed just for patients newly diagnosed with non–small cell lung cancer to help them better understand the disease and their treatment options. It includes information on treatment, ...
The Conquer Cancer Foundation of ASCO (CCF) is currently accepting applications for the 2017 Young Investigator Award (YIA) and Career Development Award (CDA).
Young Investigator Award (YIA)
A 1-year grant totaling $50,000, the YIA provides research funding to promising physicians to support the...
The Abramson Cancer Center at the University of Pennsylvania, The Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, and The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have...
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Abutalib and D’Souza explore the challenge of diagnosing and managing amyloidosis in a 70-year-old man with a history of hypertension,...
Question 1: What is the next best step for this patient?
Correct Answer: C. Determination of amyloid subtype.
Amyloidosis encompasses a heterogeneous group of diseases bound by the characteristic deposition of amyloid fibrils in soft tissues and bone marrow, and it could be...
Premenopausal women with hormone receptor–positive, HER2-negative disease and high recurrence risk… may experience improvement of 10% to 15% in 5-year breast cancer–free interval with exemestane plus ovarian function suppression vs tamoxifen alone.!-->!-->— Meredith M. Regan,...
The ASTOUND interim analysis shows that ultrasound has better incremental [breast cancer] detection than tomosynthesis in mammography-negative dense breasts at a similar [false-positive] recall rate.— Alberto S. Tagliafico, MD, and colleagues
As reported in the Journal...!-->!-->
Education about symptom management and simple exercises before initiation of treatments is an effective and simple way to prevent upper extremity dysfunction.— Jesuel Padro-Guzman, MD
With an increased number of breast cancer survivors and patients with metastatic...!-->!-->
Title: The Finest Traditions of My Calling: One Physician’s Search for the Renewal of Medicine
Author: Abraham M. Nussbaum, MD
Publisher: Yale University Press
Publication date: March 2016
Price: $28.50; hardcover, 320 pages
Doctoring isn’t what it used to be. Like ...!-->!-->
The text and photograph on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS. The photograph below, courtesy of Stanley B. Burns, MD, and The Burns Archive, is from the...
We have the opportunity to prevent the majority of anal cancers, we just need to make it [HPV vaccination] a national and global public health commitment.— Felix A. Mensah, MD
The incidence rate of human papillomavirus (HPV)-related anal cancer and its precursor lesion, ...!-->!-->
Pan Pacific Lymphoma Conference
July 18-22 • Koloa, Hawaii
For more information:
UK Breast Cancer Research Symposium
July 22-23 London, United Kingdom
For more information:
Mayo Clinic Oncology...
The University of Michigan (U-M) Board of Regents announced a $17.5 million commitment for cancer research from Madeline and Sidney Forbes of Bloomfield Hills, Michigan. This gift will create the Forbes Institute for Cancer Discovery within the U-M Comprehensive Cancer Center.
In addition, the...
Erika P. Hamilton, MD
Sarah Cannon has announced the promotion of Erika P. Hamilton, MD, to Director of the institution’s Breast and Gynecologic Cancer Research Program. Over the past 3 years, Dr. Hamilton has been instrumental in the growth and success of the program.
“Erika has quickly...!-->!-->
The American Society of Hematology (ASH) and the Leukemia & Lymphoma Society (LLS) are teaming up to raise awareness and provide education about the need for new treatments for acute myeloid leukemia (AML).
AML is a complex group of approximately 20 different types of blood cancers with a very ...
Getting to know the personal side of my medical team has increased my confidence in their professional skills, and I’m so grateful for their dedication to their patients.— Meredith Baker
Seven years ago, at age 44, I was the picture of health. I played tennis every day, ...!-->!-->
Andrew L. Kung, MD, PhD
Andrew L. Kung, MD, PhD, has been named the new Chairman of the Department of Pediatrics at Memorial Sloan Kettering Cancer Center (MSK). Dr. Kung most recently served as the Chief of the Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation at...!-->!-->
Ann G. Schwartz, PhD, MPH
Ann G. Schwartz, PhD, MPH, Deputy Center Director and Executive Vice President for Research and Academic Affairs at the Barbara Ann Karmanos Cancer Institute and Professor and Associate Chair in the Department of Oncology at Wayne State University School of...!-->!-->
Although tyrosine kinase inhibitors have dramatically increased survival for patients with chronic myeloid leukemia (CML), continuous administration of these drugs may elicit long-term toxicity, including cardiovascular adverse events. To investigate the incidence of vascular events in patients...
A Norwegian population-based study reported in the Journal of Clinical Oncology by Simer J. Bains, MD, PhD, of the Centre for Molecular Medicine Norway, University of Oslo, and colleagues showed that use of aspirin after diagnosis of colorectal cancer was associated with improved colorectal...
Although most patients with advanced ovarian cancer initially respond to platinum-based chemotherapy, they usually relapse. According to a study by Frances R. Balkwill, PhD, Professor of Cancer Biology at Barts Cancer Institute, Queen Mary University of London, United Kingdom, and colleagues...